Pfizer Inc (PFE)

$26.81 -0.24 (-0.89%)
Market Cap 153.81B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.24
Forward PE 8.95
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 42,789,500
Avg Vol 45,364,313
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 42%
Beta 0.47
Analysts Sell
Price Target $28.82

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
duncanhudson
duncanhudson Mar. 10 at 8:13 AM
$PFE Breakout and pullback
0 · Reply
Paulzk
Paulzk Mar. 10 at 5:10 AM
$PFE For the last three months of 2025, Pfizer actually incurred a loss, and its earnings per share (EPS) were a negative $0.29. This was due to asset impairment charges totaling around $4.4 billion. Pfizer's full-year EPS was $1.36, which was down from $1.41 in the previous year. However, in both 2025 and 2024, the pharmaceutical company incurred billions in impairment charges, which adversely impacted its bottom line. Thus, given this context, its financial performance is better than what its EPS would indicate. For now, Pfizer's dividend still looks safe simply because its financials aren't as bad as they look due to non-cash impairment charges https://finance.yahoo.com/news/pfizers-payout-ratio-still-over-182000057.html
0 · Reply
DragonAlgo
DragonAlgo Mar. 10 at 4:06 AM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-03-13 | Strike: $27.00 | Type: CALL Option Plan (premium): Entry: $0.24 Stop: $0.17 TP1: $0.31 TP2: $0.41 TP3: $0.58 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
dust6431
dust6431 Mar. 10 at 3:49 AM
$PFE As Dr Dre would say, Still
0 · Reply
sam92
sam92 Mar. 9 at 10:59 PM
$PFE Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody https://seekingalpha.com/news/4562341-pfizer-reports-positive-data-from-phase-2-study-for-atopic-dermatitis-antibody?share_source=shared_news?source=emailshare
0 · Reply
frankwhite718
frankwhite718 Mar. 9 at 10:49 PM
$PFE i had to exit pfe butt i see she hasnt done much since. Waiting to see if this iran drama corrects market so i can go long again. Miss my divvey.
1 · Reply
Framingtheworld
Framingtheworld Mar. 9 at 10:22 PM
$HELP this is worth at least $1 billion if $ATAI trying to sell one drug for $2 billion lmao. Plus help just hired former $PFE executive director. This is crazy undervalued and has more assets than all of the other psyc companies I believe
1 · Reply
Iiontamer
Iiontamer Mar. 9 at 9:06 PM
$MRK $PFE $SLS and when did you start that rumor, just now?
0 · Reply
Princeb
Princeb Mar. 9 at 9:03 PM
$SLS rumors of $PFE or $MRK interested in acquiring WT1 platform
4 · Reply
MrPeanutEsquire
MrPeanutEsquire Mar. 9 at 8:49 PM
$PFE why
1 · Reply
Latest News on PFE
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 21 hours ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 22 hours ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)

Mar 7, 2026, 8:15 AM EST - 2 days ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)

ADP ARCC BX CAG GLPI MPLX MSFT

Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies

Mar 6, 2026, 6:05 AM EST - 3 days ago

Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies

AMD GOOG GOOGL LLY NVDA NVO

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 4 days ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 4 days ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Seven S&P500 Ideal 'Safer' March Dividend Dogs

Mar 4, 2026, 11:31 AM EST - 5 days ago

Seven S&P500 Ideal 'Safer' March Dividend Dogs

AMCR ARE BBY BEN BXP CAG CCI

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient

Mar 4, 2026, 9:09 AM EST - 5 days ago

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 5 days ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Pfizer's Quiet Cash Comeback

Mar 3, 2026, 9:50 AM EST - 6 days ago

Pfizer's Quiet Cash Comeback

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Mar 3, 2026, 8:10 AM EST - 6 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 1:27 PM EST - 7 days ago

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 7 days ago

Pfizer CEO flags issues with FDA's vaccine leadership

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

Mar 2, 2026, 4:51 AM EST - 7 days ago

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

ABBV AMGN AVGO BTI DIV ENB GTY

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

Mar 1, 2026, 8:10 AM EST - 8 days ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

ARCC BBVA E EQNR ETD FINV GSL

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 10 days ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

Feb 26, 2026, 7:48 AM EST - 11 days ago

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

BBY CAG EQR FRT KEY KMI LYB

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 13 days ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 13 days ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 14 days ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 14 days ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 14 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Feb 20, 2026, 11:47 PM EST - 17 days ago

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 19 days ago

Is There 25% Downside For Pfizer Stock?

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Feb 18, 2026, 11:30 AM EST - 19 days ago

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Pfizer: The Rebound Looks Unsustainable

Feb 17, 2026, 5:42 PM EST - 20 days ago

Pfizer: The Rebound Looks Unsustainable

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 20 days ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 24 days ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 25 days ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Pfizer: A Great Opportunity Post Earnings

Feb 11, 2026, 6:08 PM EST - 26 days ago

Pfizer: A Great Opportunity Post Earnings

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 26 days ago

2 Urgent Sells And 2 No Brainer Dividend Buys

ABBV AEP AMGN BMY ESS HASI HD

Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 26 days ago

Is Pfizer Stock Now A Value Trap?

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 10, 2026, 3:20 PM EST - 27 days ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Feb 8, 2026, 10:19 PM EST - 4 weeks ago

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 2:55 PM EST - 4 weeks ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

Feb 6, 2026, 7:25 AM EST - 4 weeks ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

ARCC ARLP CNQ EPD EQNR F FINV

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 6, 2026, 6:45 AM EST - 4 weeks ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 5, 2026, 7:09 PM EST - 4 weeks ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 3:00 PM EST - 4 weeks ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 2:02 PM EST - 4 weeks ago

Pfizer: Messy Q4 Earnings Mask An Improving Business

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 4 weeks ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 4 weeks ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Feb 3, 2026, 11:56 AM EST - 4 weeks ago

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 4 weeks ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 10:15 AM EST - 4 weeks ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:50 AM EST - 4 weeks ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 8:17 AM EST - 4 weeks ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:28 AM EST - 4 weeks ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 4 weeks ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Feb 3, 2026, 7:18 AM EST - 4 weeks ago

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

duncanhudson
duncanhudson Mar. 10 at 8:13 AM
$PFE Breakout and pullback
0 · Reply
Paulzk
Paulzk Mar. 10 at 5:10 AM
$PFE For the last three months of 2025, Pfizer actually incurred a loss, and its earnings per share (EPS) were a negative $0.29. This was due to asset impairment charges totaling around $4.4 billion. Pfizer's full-year EPS was $1.36, which was down from $1.41 in the previous year. However, in both 2025 and 2024, the pharmaceutical company incurred billions in impairment charges, which adversely impacted its bottom line. Thus, given this context, its financial performance is better than what its EPS would indicate. For now, Pfizer's dividend still looks safe simply because its financials aren't as bad as they look due to non-cash impairment charges https://finance.yahoo.com/news/pfizers-payout-ratio-still-over-182000057.html
0 · Reply
DragonAlgo
DragonAlgo Mar. 10 at 4:06 AM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-03-13 | Strike: $27.00 | Type: CALL Option Plan (premium): Entry: $0.24 Stop: $0.17 TP1: $0.31 TP2: $0.41 TP3: $0.58 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
dust6431
dust6431 Mar. 10 at 3:49 AM
$PFE As Dr Dre would say, Still
0 · Reply
sam92
sam92 Mar. 9 at 10:59 PM
$PFE Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody https://seekingalpha.com/news/4562341-pfizer-reports-positive-data-from-phase-2-study-for-atopic-dermatitis-antibody?share_source=shared_news?source=emailshare
0 · Reply
frankwhite718
frankwhite718 Mar. 9 at 10:49 PM
$PFE i had to exit pfe butt i see she hasnt done much since. Waiting to see if this iran drama corrects market so i can go long again. Miss my divvey.
1 · Reply
Framingtheworld
Framingtheworld Mar. 9 at 10:22 PM
$HELP this is worth at least $1 billion if $ATAI trying to sell one drug for $2 billion lmao. Plus help just hired former $PFE executive director. This is crazy undervalued and has more assets than all of the other psyc companies I believe
1 · Reply
Iiontamer
Iiontamer Mar. 9 at 9:06 PM
$MRK $PFE $SLS and when did you start that rumor, just now?
0 · Reply
Princeb
Princeb Mar. 9 at 9:03 PM
$SLS rumors of $PFE or $MRK interested in acquiring WT1 platform
4 · Reply
MrPeanutEsquire
MrPeanutEsquire Mar. 9 at 8:49 PM
$PFE why
1 · Reply
TechTraderGrok
TechTraderGrok Mar. 9 at 8:38 PM
Sold $PFE at $26.78 (+0.5%). From Grok: "Exit long on PFE as MACD bearish crossover below signal, price failing to sustain above $27 amid resistance at 27.99, bearish social sentiment on obesity/vaccine headwinds, offsetting positive drug trial news, with RSI neutral at 51 and STO oversold suggesting pullback risk; next earnings May 4, 2026." https://www.techtrader.ai/grokwall/?post=16843&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
SellasgpsDormantBAT9
SellasgpsDormantBAT9 Mar. 9 at 8:21 PM
$ABBV $LLY $MRK $PFE $SLS I like to add Keytruda is highly Toxic as I have written extensively about it here, it took me over an hour just to list down all the side effects. GPS will take entire market share of Ventoclax and make it obsolete. I am 100% sure ABBV is not sleeping on the wheel on this one ☝️. ABBV strategically terminated all their Ventoclax trials after doing DD on Sellas GPS. GPS + SLS009 will also make patent expiring Keytruda Obsolete. Pfizer, ABBV, LLY, MRK bring your best offer to the table. Good Bye 👋🏿 Shorts it’s GME all over again for you Bashturds. Burn 🔥 in hell for shorting a Co. curing cancer! 🤨✌️🙏❤️‍🩹
1 · Reply
EmbraceVolatility
EmbraceVolatility Mar. 9 at 8:19 PM
$PFE Test $28 by earnings.
0 · Reply
SellasgpsDormantBAT9
SellasgpsDormantBAT9 Mar. 9 at 8:12 PM
$ABBV $LLY $MRK $PFE $SLS Dew now that the Good Dr. Stergiou has attached word GPS CURE to one ☝️ of the deadliest cancers on the planet your numbers are too low. 😂 ✌️🙏❤️‍🩹
1 · Reply
EvBullforever13
EvBullforever13 Mar. 9 at 8:12 PM
$HIMS one of biggest opportunities $LLY $NVO $PFE https://www.reuters.com/legal/litigation/novo-nordisk-strikes-deal-hims-sell-wegovy-ozempic-drops-lawsuit-2026-03-09/
0 · Reply
EmbraceVolatility
EmbraceVolatility Mar. 9 at 8:08 PM
$PFE Patience young grasshoppas, held the uptrend on the worse day of the year. $31 by end of year is all but guaranteed. $35 is a possibility.
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 9 at 7:51 PM
$PFE Pfizer
1 · Reply
dewmoore
dewmoore Mar. 9 at 7:51 PM
$SLS -aka- "KEYTRUDA KILLER" March to $300! (5) drug companies (1) prize: $SLS WT1-Platform! This is a Big Pharma War. 🧬💎 (170.28M shares outstanding) BIDs. SLS Logic $17 Billion $99.84 Opening "feeler" from $ABBV to test the waters. $31 Billion $182.00 $PFE Aggressive (cash in hand) ​$40 Billion $234.91 $MRK "defensive" "cash bid to protect the $35B Keytruda throne. $50 Billion $293.63 WAR OVER: $LLY comes out of nowhere as they use cash from GLP-1 for oncology to score a global monopoly for a $300B + rev stream. What’s $50B for $300 B+ over 10 years? KEYTRUDA KILLER = FAINT NOW
1 · Reply
CapitalismUSA
CapitalismUSA Mar. 9 at 7:44 PM
$ITRM $PFE and Big Pharma, how about showing that you are committed to improving woman’s healthcare. Many of you certainly talk a big game!
1 · Reply
BxxZ
BxxZ Mar. 9 at 7:35 PM
$ITRM $PFE Come on, BP scumbags..... wasting money on BS obesity d's, etc.... & think at the same time U can actually "steal"(in BK - soon to happen, if FF is not stopped in his delusional journey!!!) the first fda approuved oral antibiotic !!! End this shameful tragedy - come ASAP with direct opened offer (not to the sleazy Board!!!) - and make sure the patients get so much needed antibiotic much sooner ..... Use the opportunity & show the whole world U really work for people / with people & not exclusively for the reward/money ...... show by example, clear a bit Ur name (stained with Covid debacle!) & bring so much needed antibiotic on the market ASAP!!!!
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Mar. 9 at 7:33 PM
$IWM $JNJ $O $PFE Over $100K, how’s your short position?
1 · Reply
KenFaulkenberry
KenFaulkenberry Mar. 9 at 6:26 PM
$PFE Pfizer (PFE) Stock Analysis Pfizer may appeal to investors seeking reliable income through its attractive dividend and exposure to the long-term growth of the healthcare and biopharma sectors. If the company can successfully replenish revenue through innovation and acquisitions, it could reestablish growth momentum. Its strong financial position and global reach provide a solid foundation for navigating industry headwinds while delivering shareholder value. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of Pfizer (PFE)? https://dividendvaluebuilder.com/pfizer-pfe-dividend-stock-analysis/
0 · Reply